Volltext-Downloads (blau) und Frontdoor-Views (grau)

CIK Cells and HDAC Inhibitors in Multiple Myeloma

  • Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4-5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone deacetylase (HDAC) inhibitors could reduce cell viability to 59% for KMS 18 cell line and 46% for the U-266 cell line. The combined treatment led to a decrease of cell viability to 33% for KMS 18 and 27% for the U-266 cell line, thus showing a significantly better efficacy than the single treatment.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Check availability


Show usage statistics
Document Type:Article
Author:David Stephan, Hans Weiher, Ingo G. H. Schmidt-Wolf
Parent Title (English):International Journal of Molecular Sciences
First Page:945
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=28468247
Place of publication:Basel
Publishing Institution:Hochschule Bonn-Rhein-Sieg
Date of first publication:2017/04/29
Tag:CIK cells; cancer treatment; cytokine-induced killer cells; histone deacetylase inhibitors; immunotherapy; multiple myeloma
Departments, institutes and facilities:Fachbereich Angewandte Naturwissenschaften
Institut für funktionale Gen-Analytik (IFGA)
Dewey Decimal Classification (DDC):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Entry in this database:2017/05/11
Licence (German):License LogoCreative Commons - CC BY - Namensnennung 4.0 International